Lian Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lian Mao has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Carl Dahlöf
Gothenburg Migraine Clinic, c/o Läkarhuset, Södra vägen 27, S-411 35 Gothenburg, Sweden
1 shared publication - Elizabeth Loder
Harvard Medical School, Boston, MA, USA
1 shared publication - George Papadopoulos
Johnson & Johnson Pharmaceutical Services, LLC, 700 Route 202 South, Raritan, NJ 08530, USA
1 shared publication - Marcia F. T. Rupnow
Ortho-McNeil Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA
1 shared publication - Merle Diamond
Diamond Headache Clinic, Chicago, Illinois 60614, USA
1 shared publication
Latest Publications
- Open Access
- 4 October 2007
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 5 (1) , 56
The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials
Topiramate is approved for the prophylaxis (prevention) of migraine headache in adults. The most common adverse events in the three pivotal, randomized, double-blind, placebo-controlled trials were paresthesia, fatigue, cognitive impairment, anorexia, nausea, and taste alteration. In these trials, topiramate 100 mg/d significantly improved Migraine-Specific Questionnaire (MSQ) scores versus placebo (p < 0.001). The MSQ measures how much migraine limits/interrupts daily performance. Pooled analyses of pivotal trial data were conducted to further assess how topiramate 100 mg/d affects daily activities and patient functioning.
- 4 October 2007
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 5 (1) , 56
Open AccessThe impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials
Topiramate is approved for the prophylaxis (prevention) of migraine headache in adults. The most common adverse events in the three pivotal, randomized, double-blind, placebo-controlled trials were paresthesia, fatigue, cognitive impairment, anorexia, nausea, and taste alteration. In these trials, topiramate 100 mg/d significantly improved Migraine-Specific Questionnaire (MSQ) scores versus placebo (p < 0.001). The MSQ measures how much migraine limits/interrupts daily performance. Pooled analyses of pivotal trial data were conducted to further assess how topiramate 100 mg/d affects daily activities and patient functioning.